<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00957879</url>
  </required_header>
  <id_info>
    <org_study_id>2009P000567</org_study_id>
    <secondary_id>K23DK073356</secondary_id>
    <nct_id>NCT00957879</nct_id>
  </id_info>
  <brief_title>Different Vitamin D Preparations &amp; FGF23 in Humans</brief_title>
  <official_title>Effect of Different Vitamin D Preparations on Circulating FGF23 Levels in Vitamin D Deficient Caucasian and African-American Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fibroblast growth factor 23 (FGF23) is a new hormone which controls phosphate and vitamin D
      levels in humans. Excess FGF23 is associated with an increased risk of death in patients with
      chronic kidney disease. In this study the investigators are investigating the effects of
      different forms of vitamin D on FGF23 levels in the blood in order to increase our
      understanding of how this important hormone works.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fibroblast growth factor 23 (FGF23) is a novel hormone involved in phosphate and vitamin D
      physiology. X-linked hypophosphatemia (XLH), autosomal dominant hypophosphatemic rickets
      (ADHR), and tumor induced osteomalacia (TIO) are 3 rare diseases characterized by
      rickets/osteomalacia, fractures, and hypophosphatemia secondary to renal phosphate wasting
      and inappropriately low levels of activated vitamin D (calcitriol), which are caused by
      excess amounts of or mutated FGF23. FGF23 excess also occurs in renal failure, where elevated
      FGF23 levels predict increased mortality. Thus, abnormal FGF23 appears to be central to both
      rare and common diseases. While FGF23 appears to be regulated by vitamin D, dietary and serum
      phosphate, much is still unknown. The effects of different forms of vitamin D on FGF23
      stimulation are not well characterized. Similarly, any racial differences in the regulation
      of FGF23 by vitamin D have not been investigated.

      To address these knowledge deficits, we will randomize 52 vitamin D deficient (25OHD &lt; or =
      24 ng/mL by LC/MS) Caucasian and African-American men and women to treatment with either
      dietary vitamin D or activated vitamin D for 12 weeks. Our primary endpoint will be the
      change in FGF23 with dietary versus activated vitamin D.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in FGF23 levels</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum phosphate</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary phosphate</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum calcium</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>ergocalciferol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weekly ergocalciferol for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>calcitriol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily calcitriol for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ergocalciferol</intervention_name>
    <description>Ergocalciferol 50000 international units by mouth weekly for 12 weeks</description>
    <arm_group_label>ergocalciferol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcitriol</intervention_name>
    <description>Calcitriol 0.5 mcg by mouth daily for 12 weeks</description>
    <arm_group_label>calcitriol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 45 yrs

          -  Serum 25OHD &lt; 24 ng/mL by liquid chromatography/mass spectroscopy

          -  At least 1 menses in the last 3 months (females) and normal serum testosterone (males)

          -  African-American or Caucasian race

        Exclusion Criteria:

          -  Significant cardiac, hepatic, oncologic, or psychiatric disease

          -  History of malabsorption, kidney stones, or recent alcohol excess/abuse

          -  Use of medications known to affect serum phosphate levels including phosphate-binding
             antacids, sodium etidronate, calcitonin, excessive doses of vitamin D (&gt; 1000 units
             per day), excessive doses of vitamin A (&gt; 20,000 units/day), calcitriol, growth
             hormone, or anti-convulsants

          -  Use of thiazide diuretics or cholestyramine

          -  Serum calcium &lt; 8 or &gt; 11 mg/dL, creatinine &gt; 1.5 mg/dL, or Hgb &lt; 11 gm/dL

          -  Serum glucose &gt;140mg/dL

          -  Liver function tests &gt; 2 times the upper limit of normal

          -  TSH &lt; 0.1 or &gt; 7 uU/mL

          -  WBC &lt; 2,000 or &gt; 15,000/cmm

          -  Platelet count &lt; 100,000 or &gt; 500,000/cum

          -  Hormone replacement therapy (however, oral contraceptives are allowed) or testosterone
             use

          -  Urine beta-hCG positive (females)

          -  Serum phosphate &gt; 4.6 mg/dL

          -  Allergy to vitamin D
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherri-Ann M Burnett-Bowie, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Burnett SM, Gunawardene SC, Bringhurst FR, Jüppner H, Lee H, Finkelstein JS. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res. 2006 Aug;21(8):1187-96.</citation>
    <PMID>16869716</PMID>
  </reference>
  <reference>
    <citation>Bhan I, Shah A, Holmes J, Isakova T, Gutierrez O, Burnett SM, Jüppner H, Wolf M. Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'? Kidney Int. 2006 Oct;70(8):1486-94. Epub 2006 Aug 30.</citation>
    <PMID>16941023</PMID>
  </reference>
  <reference>
    <citation>Burnett-Bowie SM, Mendoza N, Leder BZ. Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men. Bone. 2007 Apr;40(4):913-8. Epub 2006 Dec 8.</citation>
    <PMID>17157573</PMID>
  </reference>
  <reference>
    <citation>Burnett-Bowie SM, Henao MP, Dere ME, Lee H, Leder BZ. Effects of hPTH(1-34) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D, and FGF23 levels in healthy men. J Bone Miner Res. 2009 Oct;24(10):1681-5. doi: 10.1359/jbmr.090406.</citation>
    <PMID>19419295</PMID>
  </reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2009</study_first_submitted>
  <study_first_submitted_qc>August 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2009</study_first_posted>
  <last_update_submitted>April 18, 2012</last_update_submitted>
  <last_update_submitted_qc>April 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Sherri-Ann M. Burnett-Bowie</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>FGF23</keyword>
  <keyword>FGF-23</keyword>
  <keyword>Phosphate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

